Hycamtin

Topotecan HCl

Metastatic ovarian carcinoma after failure of initial or subsequent chemotherapy; small cell lung cancer sensitive disease after failure of 1st-line chemotherapy. In combination w/ cisplatin for the treatment of histologically confirmed stage IV-B, recurrent or persistent carcinoma of the cervix.

Ovarian & small cell lung carcinoma 1.5 mg/m² by IV infusion over 30 min daily for 5 consecutive days, starting on day 1 of 21-day course. A min of 4 courses is recommended. In the event of severe neutropenia during any course, reduce dose by 0.25 mg/m² for subsequent courses. Alternatively, G-CSF may be given following the subsequent courses (before resorting to dose reduction) starting from day 6, 24 hr after the completion of topotecan administration. Cervical cancer Initial dose: 0.75 mg/m² by IV infusion over 30 min daily on days 1, 2 & 3. Administer cisplatin IV infusion 50 mg/m² on day 1 & following topotecan dose. Repeat every 21 days for 6 courses or until progressive disease.

Hypersensitivity. Severe bone marrow depression as evidenced by baseline neutrophil count <1.5 x 10⁹/L &/or platelet count ≤100 x 10⁹/L. Pregnancy & lactation.

Monitor FBC including platelets regularly. Myelosuppression, neutropenia which can cause neutropenic colitis. History of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation & use of pneumotoxic drugs &/or colony-stimulating factors; monitor for pulmonary symptoms of ILD eg, cough, fever, dyspnoea, &/or hypoxia. Discontinue in case of new diagnosis of ILD. Diarrhoea. May impair ability to drive or operate machinery.

Infection, anaemia, febrile neutropenia, leucopenia, neutropenia, thrombocytopenia, anorexia, diarrhoea, nausea & vomiting, abdominal pain, constipation, stomatitis, alopecia, asthenia, fatigue, pyrexia.

Greater myelosuppression w/ other cytotoxic agents (eg, paclitaxel or etoposide) & platinum-containing agents (eg, cisplatin or carboplatin). Duration of neutropenia prolonged by G-CSF.

Cytotoxic Chemotherapy

L01CE01 - topotecan ; Belongs to the class of Topoisomerase 1 (TOP1) inhibitors. Used in the treatment of cancer.

S